August 30, 2022
The cell and gene therapy company’s lead in vivo candidate uses lentiviral vector delivery to correct metabolic disorder in large animal model of hereditary tyrosinemia type-1
Read MoreMay 25, 2022
Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa
Read MoreJanuary 10, 2022
Company adds in vivo capabilities to existing ex vivo approach for development of novel gene therapies
Read MoreOctober 21, 2021
RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available
Read MoreSeptember 29, 2021
Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments
Read MoreApril 20, 2021
Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial
Read More